Jiangsu Recbio Technology Co., Ltd. (02179.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 4Aug 7Aug 12Aug 17Aug 20Aug 25Aug 28Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.4x

Market Cap

HKD 3.10B

MomentumView details →

1D Return

+0.00%

YTD Return

+25.00%

RSI (14)

49.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.4x

Market Cap

HKD 3.10B

RSI (14)

49.1

MomentumView details →

1D Return

+0.00%

YTD Return

+25.00%

ProfitabilityView details →

Gross Margin

−55.02%

Net Margin

−2937.18%

EBITDA Margin

−2430.98%

ROE (TTM)

−226.52%

ROA (TTM)

−70.68%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

−25.21%

EPS YoY

+14.11%

FCF YoY

+42.52%

Revenue CAGR 3Y

+32.53%

EPS CAGR 3Y

+3.45%

EBITDA YoY

+23.17%

EarningsView details →

EPS (Actual)

−HKD 0.39

EPS Surprise

49.52%

Beats (12Q)

1/12

Next Q EPS Est

−HKD 0.78

Avg Surprise (4Q)

49.52%

Rev Surprise

356.48%

Capital & dividendView details →

Debt/Equity

1.35x

Current Ratio

0.53x

Quick Ratio

0.45x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

38.41M

Net Income (TTM)

−1.13B

Op. CF (TTM)

−730.36M

Next earningsApr 1, 2027 →

Latest newsMore news →

RecBio (02179.HK) reported interim results for the six months ended June 2026, with revenue of RMB 47,000, down 99.6% year-on-year, and a narrowed net loss of RMB 212 million, compared with a loss of RMB 341 million in the same period last year.16d ago

Similar companies

Celldex Therapeutics, Inc.CLDX 凯因科技688687.SH 南模生物688265.SH uniQure N.V.QURE Beam Therapeutics Inc.BEAM Disc Medicine, Inc.IRON Find similar companies →

Latest newsMore news →

RecBio (02179.HK) reported interim results for the six months ended June 2026, with revenue of RMB 47,000, down 99.6% year-on-year, and a narrowed net loss of RMB 212 million, compared with a loss of RMB 341 million in the same period last year.16d ago